By InvitationPhase 2

ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study

United States225 participantsStarted 2022-07-12

Plain-language summary

The purpose of this study is to evaluate the long-term safety of GT005 in participants with Geographic Atrophy (GA) secondary to AMD who have been treated in an antecedent study.

Who can participate

Age range55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Able and willing to give written informed consent
✓. Received GT005 in an antecedent study, GT005-01 (FOCUS, NCT03846193), GT005-02 (EXPLORE, NCT04437368) and GT005-03 (HORIZON, NCT04566445)
✓. Willing to attend study visits and complete the study procedures.

What they're measuring

Incidence and severity of ocular and systemic adverse events (AEs)

Timeframe: up to Week 260

Trial details

NCT IDNCT05481827

SponsorGyroscope Therapeutics Limited

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2028-06-02

View on ClinicalTrials.gov More Age Related Macular Degeneration (AMD) trials